CELC

Celcuity Inc. (CELC) | Rumor.io

Celcuity

CELC

Attention (50-day avg)0%

Attention rank (50-day avg)#876

Bullish sentiment (50-day avg)69%

Price to earnings ratio-21

Market capitalization3.9B

Earnings per share-4.3

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-177M

Social

What share of all stock conversation is about CELC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 14

Analysts HC Wainwright and Stifel maintain Buy ratings on Celcuity, with Stifel lowering its price target from $175 to $150.
Celcuity's FDA-approved status and $600M war chest are seen as positives, with one analyst noting a hold over 90% of the stock's price would be very positive.
Despite target cuts, analysts maintain strong upside potential for Celcuity, with Stifel's new target still $25 above its previous one.

Generated by AI

Sentiment

Of the messages about CELC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +25	66.67% -16.85	82.57% +5.16
Bearish	0% 0	0% -25	33.33% +16.85	17.43% -5.16

Bullish· Jul 15

$CELC is a strong buying opportunity, with the company's market capitalization wiped out by a single quarter delay, making it a great time to buy.
The FDA approval is a significant catalyst, with the stock likely to gap up 5x to 15x on the news, and analysts may raise their price targets following the regulatory outcome.
With a strong buy consensus from 12 analysts, an average price target of $160.64, and a potential upside of 30-50% from current levels, $CELC is a compelling investment opportunity.

Bearish· Jun 2

$CELC's recent performance has been disappointing, with some investors feeling that the stock has fallen short of high market expectations.
The company's Phase 3 trial results, while showing promise, may not have met investors' high hopes, leading to a "sell the news" reaction and a decline in the stock price.
$CELC's chart shows a gap around $65, suggesting that the stock may be due for a bounce or a reevaluation of its value, but the current trend is bearish.

Generated by AI

Topics

Of the messages about CELC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	71.7%	29.19%
Technical Analysis	—	0%	5.66%	5.06%
Analysts	—	0%	22.64%	23.84%
Earnings	—	0%	0%	20.68%
Macro	—	0%	0%	21.24%
Controversies	—	0%	0%	0%

Announcements· Oct 20

Celcuity Inc. ($CELC) announced detailed efficacy and safety results from the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib in adults with hormone receptor positive (HR+), HER2-negative, PIK3CA wild-type advanced breast cancer.
The trial showed gedatolisib significantly improves survival in HR+/HER2- breast cancer patients, with analysts raising the price target to $95.
The success of $CELC highlights the shift from small-molecule drugs to targeted biotech, with precision being the future of pharma, not scale.

Technical Analysis· Jul 28

The stock has a strong breakout potential, with a possible price target of $32-$30.00, but may face a wall at $40.00.
The stock has shown a strong reversal after reaching $35, and needs to break through $40 to continue its upward momentum.
The stock has a high risk of bleeding heavily when shorts start, and may see a flush to $18, but it could also push back to $41-42+.

Generated by AI

Community

Of the messages about CELC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	20%	71.11%	47.89%	41.94%
Newcomers	80%	28.89%	52.11%	58.06%

Regulars· Aug 14

Analysts Needham and Stifel maintain their BUY ratings on Celcuity despite trimming valuation targets after earnings, with Needham lowering its target from $157 to $140 and Stifel from $175 to $150.
The FDA approval of Revtorpyk, a pan-PI3K inhibitor, is seen as a major catalyst for Celcuity's stock, with analysts expecting significant upside potential.
Despite a recent sell-off, regulars are focusing on the positive aspects of Celcuity's fundamentals, including its $600M war chest and the potential for future sales and revenue growth.

Newcomers· Jul 17

Many newcomers are astonished by the market's reaction to FDA approval, with some wondering if the drop is due to a delay or a larger issue.
Some newcomers are optimistic about Celcuity's potential, with one user suggesting it could be a "nice portfolio cornerstone" and another predicting it will reach $100+ in the next 4-8 weeks.
Newcomers are also focused on the company's management, with one user expressing disappointment in their handling of the approval call and another noting that the company needs cash, which could lead to dilution and risk.

Generated by AI

News

Why is Celcuity stock climbing today?

12d agoInvesting.com

JPMorgan Initiates Celcuity With Overweight Rating, $157 Price Target

Celcuity (CELC) has an average rating of buy and mean price target of $160.75, according to analysts

13d agoYahoo Finance

Celcuity To Participate in Upcoming Investor Conferences

MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Wells Fargo 21st Annual Healthcare Conference at 10:15 a.m. EDT on T

28d agoYahoo Finance

Also Discussed

Investors talking about CELC also mention

#	Name	Attention
1	IDEAYA Biosciences Inc.IDYA	0%-0.01
2	Abivax SAABVX	0.01%-0.01
3	Revolution Medicines, Inc.RVMD	0.01%-0.01
4	Crinetics Pharmaceuticals IncCRNX	0%new
5	Elicio Therapeutics Inc.ELTX	0%0
6	Nuvalent, Inc.NUVL	0%0
7	HOUS - Anywhere Real Estate Inc.	——
8	Smith Douglas Homes CorporationSDHC	0%0
9	Global Business Travel Group, Inc.GBTG	0%new
10	STAI - ScanTech AI Systems Inc.	——

Celcuity Inc.

Healthcare
Biotechnology

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company’s current work centers on cancer treatments that act on the PAM pathway, including its lead therapeutic candidate gedatolisib, which is being developed for advanced breast cancer and metastatic castration-resistant prostate cancer. Celcuity also operates a cellular analysis platform used to identify abnormal signaling activity in tumors and help guide the development of precision oncology therapies. Its business is concentrated in oncology drug development, with programs aimed at patients whose cancers are driven by specific molecular pathways. Headquartered in Minneapolis, Minnesota, Celcuity is positioned as a research-driven biotech company working across therapeutic development and biomarker-based cancer analysis.

Website

Location

16305 36th Avenue North

Minneapolis, MN, 55446

United States

Social

What share of all stock conversation is about CELC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 14

Analysts HC Wainwright and Stifel maintain Buy ratings on Celcuity, with Stifel lowering its price target from $175 to $150.
Celcuity's FDA-approved status and $600M war chest are seen as positives, with one analyst noting a hold over 90% of the stock's price would be very positive.
Despite target cuts, analysts maintain strong upside potential for Celcuity, with Stifel's new target still $25 above its previous one.

Generated by AI

Sentiment

Of the messages about CELC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +25	66.67% -16.85	82.57% +5.16
Bearish	0% 0	0% -25	33.33% +16.85	17.43% -5.16

Bullish· Jul 15

$CELC is a strong buying opportunity, with the company's market capitalization wiped out by a single quarter delay, making it a great time to buy.
The FDA approval is a significant catalyst, with the stock likely to gap up 5x to 15x on the news, and analysts may raise their price targets following the regulatory outcome.
With a strong buy consensus from 12 analysts, an average price target of $160.64, and a potential upside of 30-50% from current levels, $CELC is a compelling investment opportunity.

Bearish· Jun 2

$CELC's recent performance has been disappointing, with some investors feeling that the stock has fallen short of high market expectations.
The company's Phase 3 trial results, while showing promise, may not have met investors' high hopes, leading to a "sell the news" reaction and a decline in the stock price.
$CELC's chart shows a gap around $65, suggesting that the stock may be due for a bounce or a reevaluation of its value, but the current trend is bearish.

Generated by AI

Topics

Of the messages about CELC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	71.7%	29.19%
Technical Analysis	—	0%	5.66%	5.06%
Analysts	—	0%	22.64%	23.84%
Earnings	—	0%	0%	20.68%
Macro	—	0%	0%	21.24%
Controversies	—	0%	0%	0%

Announcements· Oct 20

Celcuity Inc. ($CELC) announced detailed efficacy and safety results from the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib in adults with hormone receptor positive (HR+), HER2-negative, PIK3CA wild-type advanced breast cancer.
The trial showed gedatolisib significantly improves survival in HR+/HER2- breast cancer patients, with analysts raising the price target to $95.
The success of $CELC highlights the shift from small-molecule drugs to targeted biotech, with precision being the future of pharma, not scale.

Technical Analysis· Jul 28

The stock has a strong breakout potential, with a possible price target of $32-$30.00, but may face a wall at $40.00.
The stock has shown a strong reversal after reaching $35, and needs to break through $40 to continue its upward momentum.
The stock has a high risk of bleeding heavily when shorts start, and may see a flush to $18, but it could also push back to $41-42+.

Generated by AI

Community

Of the messages about CELC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	20%	71.11%	47.89%	41.94%
Newcomers	80%	28.89%	52.11%	58.06%

Regulars· Aug 14

Analysts Needham and Stifel maintain their BUY ratings on Celcuity despite trimming valuation targets after earnings, with Needham lowering its target from $157 to $140 and Stifel from $175 to $150.
The FDA approval of Revtorpyk, a pan-PI3K inhibitor, is seen as a major catalyst for Celcuity's stock, with analysts expecting significant upside potential.
Despite a recent sell-off, regulars are focusing on the positive aspects of Celcuity's fundamentals, including its $600M war chest and the potential for future sales and revenue growth.

Newcomers· Jul 17

Many newcomers are astonished by the market's reaction to FDA approval, with some wondering if the drop is due to a delay or a larger issue.
Some newcomers are optimistic about Celcuity's potential, with one user suggesting it could be a "nice portfolio cornerstone" and another predicting it will reach $100+ in the next 4-8 weeks.
Newcomers are also focused on the company's management, with one user expressing disappointment in their handling of the approval call and another noting that the company needs cash, which could lead to dilution and risk.

Generated by AI

Celcuity

Social

Aug 14

Bullish· Jul 15

Bearish· Jun 2

Announcements· Oct 20

Technical Analysis· Jul 28

Regulars· Aug 14

Newcomers· Jul 17

Why is Celcuity stock climbing today?

JPMorgan Initiates Celcuity With Overweight Rating, $157 Price Target

JPMorgan initiates Celcuity stock coverage with overweight rating

Celcuity at citigroup’s biopharma back to school summit: launch begins

Celcuity at Wells Fargo healthcare conference: launch, data in focus

Celcuity To Participate in Upcoming Investor Conferences

Also Discussed

Celcuity Inc.

Company Information

Location

Why is Celcuity stock climbing today?

JPMorgan Initiates Celcuity With Overweight Rating, $157 Price Target

JPMorgan initiates Celcuity stock coverage with overweight rating

Celcuity at citigroup’s biopharma back to school summit: launch begins

Celcuity at Wells Fargo healthcare conference: launch, data in focus

Celcuity To Participate in Upcoming Investor Conferences

Also Discussed

Social

Aug 14

Bullish· Jul 15

Bearish· Jun 2

Announcements· Oct 20

Technical Analysis· Jul 28

Regulars· Aug 14

Newcomers· Jul 17